Dyne Therapeutics, Inc.
General ticker "DYN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.8B (TTM average)
Dyne Therapeutics, Inc. follows the US Stock Market performance with the rate: 33.7%.
Estimated limits based on current volatility of 3.3%: low 14.75$, high 15.76$
Factors to consider:
- Total employees count: 258 (+35.1%) as of 2025
- Top business risk factors: Need additional capital, High risk of clinical failure, Regulatory and compliance, Manufacturing issues, Market competition
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [13.26$, 32.41$]
- 2026-12-31 to 2027-12-31 estimated range: [9.88$, 25.29$]
Financial Metrics affecting the DYN estimates:
- Negative: with PPE of -5.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: 0.07 < Interest expense per share per price, % of 0.24
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
Short-term DYN quotes
Long-term DYN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $242.16MM | $343.89MM | $468.18MM |
| Operating Income | $-242.16MM | $-343.89MM | $-468.18MM |
| Non-Operating Income | $6.22MM | $26.92MM | $21.97MM |
| Interest Expense | $0.00MM | $0.00MM | $6.19MM |
| R&D Expense | $210.76MM | $281.41MM | $398.33MM |
| Income(Loss) | $-235.94MM | $-316.96MM | $-446.21MM |
| Net Income(Loss)* | $-235.94MM | $-317.42MM | $-446.21MM |
| Stockholders Equity | $91.29MM | $629.84MM | $972.13MM |
| Assets | $165.08MM | $691.23MM | $1,186.96MM |
| Operating Cash Flow | $-188.16MM | $-292.37MM | $-403.21MM |
| Capital expenditure | $0.73MM | $2.38MM | $1.92MM |
| Investing Cash Flow | $83.31MM | $-204.08MM | $-28.75MM |
| Financing Cash Flow | $54.32MM | $809.89MM | $890.31MM |
| Earnings Per Share** | $-3.95 | $-3.37 | $-3.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.